Molbio Diagnostics Ltd
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-
of-care (POC) molecular diagnostics
company engaged in the research,
development, manufacturing, and commercialization of rapid diagnostic
solutions.[1]
- Market Cap ₹ 10,039 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 69.0
- Book Value ₹
- Dividend Yield %
- ROCE 21.2 %
- ROE 15.8 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 11.9%
- Debtor days have improved from 151 to 85.6 days.
Cons
- Company has a low return on equity of 11.9% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 1,271 | 776 | 327 | 756 | 971 | |
| 676 | 457 | 286 | 552 | 746 | |
| Operating Profit | 595 | 319 | 40 | 204 | 226 |
| OPM % | 47% | 41% | 12% | 27% | 23% |
| 1 | 5 | 8 | -21 | -2 | |
| Interest | 35 | 25 | 6 | 8 | 9 |
| Depreciation | 12 | 42 | 19 | 24 | 26 |
| Profit before tax | 549 | 258 | 23 | 152 | 188 |
| Tax % | 25% | 27% | 32% | 27% | 26% |
| 410 | 187 | 16 | 111 | 140 | |
| EPS in Rs | 2,027.06 | 833.37 | 69.00 | 493.01 | 62.00 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 8% |
| TTM: | 28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -8% |
| TTM: | 14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 27% |
| 3 Years: | 12% |
| Last Year: | 16% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 |
| Reserves | 333 | 681 | 737 | 848 | 988 |
| 257 | 105 | 57 | 70 | 26 | |
| 215 | 85 | 123 | 157 | 291 | |
| Total Liabilities | 806 | 874 | 920 | 1,077 | 1,307 |
| 55 | 182 | 189 | 209 | 215 | |
| CWIP | 100 | 0 | 0 | 2 | 18 |
| Investments | 9 | 9 | 54 | 54 | 95 |
| 643 | 683 | 676 | 813 | 980 | |
| Total Assets | 806 | 874 | 920 | 1,077 | 1,307 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 344 | 98 | 68 | 38 | 249 | |
| -142 | -87 | -51 | -31 | -98 | |
| -192 | -20 | 31 | -24 | -17 | |
| Net Cash Flow | 10 | -9 | 48 | -18 | 133 |
| Free Cash Flow | 212 | 35 | 55 | 24 | 206 |
| CFO/OP | 78% | 53% | 251% | 39% | 139% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 61 | 113 | 194 | 174 | 86 |
| Inventory Days | 261 | 402 | 885 | 393 | 395 |
| Days Payable | 124 | 64 | 201 | 129 | 226 |
| Cash Conversion Cycle | 198 | 450 | 877 | 438 | 254 |
| Working Capital Days | 75 | 206 | 479 | 239 | 155 |
| ROCE % | 41% | 4% | 22% | 21% |
Documents
Annual reports
No data available.